AWM
PMCB icon

Accredited Wealth Management’s PharmaCyte Biotech PMCB Stock Holding History

Accredited Wealth Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1 Buy
+50
New +$50 ﹤0.01% 381

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Accredited Wealth Management's PMCB Position: Q3 2025 in Review

Accredited Wealth Management opened a new position in PharmaCyte Biotech (PMCB) in Q3 2025: 50 shares worth $1. The stake represents ﹤0.01% of the portfolio and ranks #381 among its holdings.

23 funds tracked by Wall St. Rank hold PMCB as of Q3 2025.

  • Accredited Wealth Management held 50 shares of PharmaCyte Biotech worth $1 as of Q3 2025.
  • PharmaCyte Biotech was a new Accredited Wealth Management position in Q3 2025.
  • PharmaCyte Biotech made up ﹤0.01% of Accredited Wealth Management's portfolio in Q3 2025, its #381 holding.
  • 23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2025.

Based on Accredited Wealth Management's 13F filing for Q3 2025, filed 12 Nov 2025.